Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Cabergoline monotherapy in the long-term treatment of Cushing's disease

Abstract

Background: Cabergoline is a long-acting dopamine receptor agonist used to treat prolactinomas. Identification of D 2 receptors in corticotroph tumors led to clinical trials of cabergoline therapy in limited cases of Nelson's syndrome, ectopic ACTH-secreting tumors, and recently Cushing's disease (CD). Objective: To evaluate the long-term efficacy of cabergoline monotherapy in patients with CD. Methods: Retrospective analysis of non-randomized clinical therapy with cabergoline in 30 patients with CD treated in academic centers of Buenos Aires and Montreal. Cabergoline was initiated at 0.5–1.0 mg/week and adjusted up to a maximal dose of 6 mg/week based on urinary free cortisol (UFC) levels. Complete response to cabergoline was defined as a sustained normalization of UFC with at least two normal values measured at 1–3 months interval; partial response was defined as a decrease of UFC to <125% of the upper limit of normal, and treatment failure as UFC ≥125% of it. Results: Within 3–6 months, complete response was achieved in 11 patients (36.6%) and partial response in 4 patients (13.3%). After long-term therapy, nine patients (30%) remain with a complete response after a mean of 37 months (range from 12 to 60 months) with a mean dose of 2.1 mg/week of cabergoline. Two patients escaped after 2 and 5 years of complete response, but one patient transiently renormalized UFC after an increase in cabergoline dosage. No long-term response was maintained in four initial partial responders. Conclusions: Cabergoline monotherapy can provide an effective long-term medical therapy for selected patients with CD, but requires close follow-up for dose adjustments.

Overview

Integrity signals

Registry

Crossref · 10.1530/eje-10-0382

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Research works printed but not linked: 1

  1. 2007, Research in veterinary science, 85, 26

Cited by

See all 202

Metadata

Authors
Godbout, A., Manavela, M., Danilowicz, K., Beauregard, H., Bruno, O. D., & Lacroix, A.
Affiliations
  • Centre Hospitalier de l’Université de Montréal (CA)
  • Universidad de Buenos Aires (AR)
Corresponding author
Lacroix, André
Venue
European Journal of Endocrinology
Published
2010-11
Volume
163
Issue
5
Pages
709-716
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2117410545
Cited by
202
References
35
Citations by year
2026: 7 · 2025: 5 · 2024: 7 · 2023: 8 · 2022: 10 · 2021: 7 · 2020: 10 · 2019: 16 · 2018: 21 · 2017: 10 · 2016: 14 · 2015: 26 · 2014: 19 · 2013: 27 · 2012: 12
FWCI
9.89
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
Keywords
cabergoline, Cushing's disease, dopamine agonists, long-term monotherapy, urinary free cortisol, treatment response, dose adjustment, pituitary ACTH-secreting tumor, corticotroph adenoma
MeSH terms
Cabergoline, Adult, Aged, Ergolines, Female, Follow-Up Studies, Humans, Hydrocortisone, Male, Middle Aged, Recurrence, Retrospective Studies, Time Factors, Cohort Studies, Pituitary ACTH Hypersecretion, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cabergoline monotherapy in the long-term treatment of Cushing's disease. https://app.cochat.ai/papers/10.1530/eje-10-0382
The paper
Godbout, A., Manavela, M., Danilowicz, K., Beauregard, H., Bruno, O. D., & Lacroix, A. (2010). Cabergoline monotherapy in the long-term treatment of Cushing's disease. European Journal of Endocrinology. https://doi.org/10.1530/eje-10-0382

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.